The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma

BACKGROUND: The response rate of immunotherapy via immune checkpoint blockade in hepatocellular carcinoma (HCC) is limited due to multiple immune evasion mechanisms. OX40 is a T cell co-stimulating molecule which suppresses the cancer immune evasion by activating effector T cells (Teffs) and counter...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Zhimei, Lin, Liteng, An, Yongcheng, Zhan, Meixiao, Chen, Ye, Cai, Mingyue, Zhu, Xiaojing, Lu, Ligong, Zhu, Kangshun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197594/
https://www.ncbi.nlm.nih.gov/pubmed/34136421
http://dx.doi.org/10.2147/JHC.S301375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197594/
https://www.ncbi.nlm.nih.gov/pubmed/34136421
http://dx.doi.org/10.2147/JHC.S301375

Ejemplares similares